チロシンプロテインキナーゼ受容体UFO治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0469
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:185
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥371,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥742,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,113,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Tyrosine Protein Kinase Receptor UFO – Pipeline Review, H2 2019
Summary

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response.

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 7, 10 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Non Malignant Disorders and Respiratory which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor, Gastric Cancer, Breast Cancer, Melanoma, Metastatic Colorectal Cancer, Ovarian Cancer, Metastatic Melanoma, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Cervical Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Ewing Sarcoma, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Osteosarcoma, Pancreatic Cancer, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Thyroid Cancer, Wilms’ Tumor (Nephroblastoma), Adenocarcinoma, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bile Duct Cancer (Cholangiocarcinoma), Bone Metastasis, Carcinoid Tumor, Colon Cancer, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), High-Grade Glioma, Idiopathic Pulmonary Fibrosis, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liposarcoma, Liver Cancer, Lung Adenocarcinoma, Malignant Mesothelioma, Mantle Cell Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Non-Alcoholic Steatohepatitis (NASH), Non-Hodgkin Lymphoma, Non-Rhabdomyosarcoma, Non-Small Cell Lung Carcinoma, Oral Cavity (Mouth) Cancer, Osteolytic Bone Metastasis, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Paraganglioma (Glomus Jugulare Tumor), Penile Cancer, Peritoneal Cancer, Pheochromocytoma, Plexiform Neurofibroma, Prostate Cancer, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Salivary Gland Cancer, Squamous Cell Carcinoma, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Thrombosis, Thymoma (Thymic Epithelial Tumor), Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer and Uterine Cancer.

The latest report Tyrosine Protein Kinase Receptor UFO – Pipeline Review, H2 2019, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
- The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Overview
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Companies Involved in Therapeutics Development
Arcus Biosciences Inc
Astellas Pharma Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Daiichi Sankyo Co Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
F1 Oncology Inc
Genosco Inc
HEC Pharm Co Ltd
Hope Biosciences Inc
Incyte Corp
Konruns Pharmaceutical Co Ltd
Mirati Therapeutics Inc
Novithera SAS
Ono Pharmaceutical Co Ltd
Oribase Pharma
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Symphogen A/S
Takeda Pharmaceutical Co Ltd
TamRx LLC
Tolero Pharmaceuticals Inc
Vichem Chemie Research Ltd
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bemcentinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-149 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-9016 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cabometyx – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Dormant Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arcus Biosciences Inc, H2 2019
Pipeline by Astellas Pharma Inc, H2 2019
Pipeline by BerGenBio ASA, H2 2019
Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019
Pipeline by Celldex Therapeutics Inc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Exelixis Inc, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by F1 Oncology Inc, H2 2019
Pipeline by Genosco Inc, H2 2019
Pipeline by HEC Pharm Co Ltd, H2 2019
Pipeline by Hope Biosciences Inc, H2 2019
Pipeline by Incyte Corp, H2 2019
Pipeline by Konruns Pharmaceutical Co Ltd, H2 2019
Pipeline by Mirati Therapeutics Inc, H2 2019
Pipeline by Novithera SAS, H2 2019
Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Pipeline by Oribase Pharma, H2 2019
Pipeline by Qurient Co Ltd, H2 2019
Pipeline by Rigel Pharmaceuticals Inc, H2 2019
Pipeline by SignalChem Lifesciences Corp, H2 2019
Pipeline by Symphogen A/S, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by TamRx LLC, H2 2019
Pipeline by Tolero Pharmaceuticals Inc, H2 2019
Pipeline by Vichem Chemie Research Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019

【掲載企業】

Arcus Biosciences Inc
Astellas Pharma Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Daiichi Sankyo Co Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
F1 Oncology Inc
Genosco Inc
HEC Pharm Co Ltd
Hope Biosciences Inc
Incyte Corp
Konruns Pharmaceutical Co Ltd
Mirati Therapeutics Inc
Novithera SAS
Ono Pharmaceutical Co Ltd
Oribase Pharma
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SignalChem Lifesciences Corp
Symphogen A/S
Takeda Pharmaceutical Co Ltd
TamRx LLC
Tolero Pharmaceuticals Inc
Vichem Chemie Research Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[チロシンプロテインキナーゼ受容体UFO治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆